Chronotherapy – the specific timing of drug delivery – has shown promise in clinical trials. But that may not be enough to overcome the practical challenges.
The next big revolution in pharmaceuticals could be miniature production systems – small enough to fit in a briefcase.
A war on “prediabetes” has created millions of new patients and a tempting opportunity for pharma. But how real is the condition?